Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains

Clinical Proteomics

Eleftherios P Diamandis³  Lili-Naz Hazrati²  Uros Kuzmanov¹  Phedias Diamandis⁴  Apostolos Dimitromanolakis¹  Eduardo Martínez-Morillo¹  Hari Kosanam¹  Ilijana Begcevic¹ 

[1] Samuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada;Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada;Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St., Box 32, Floor 6, Rm. L6-201, Toronto, ON, M5T 3L9, Canada;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

关键词: Mass spectrometry;    Human brain;    Hippocampus;    Cerebrospinal fluid;    Alzheimer’s disease;   

Others  :  1026345
DOI  :  10.1186/1559-0275-10-5

 received in 2013-03-15, accepted in 2013-04-05,  发布年份 2013

【 摘 要 】

Background

Alzheimer’s disease (AD) is the most common type of dementia affecting people over 65 years of age. The hallmarks of AD are the extracellular deposits known as amyloid β plaques and the intracellular neurofibrillary tangles, both of which are the principal players involved in synaptic loss and neuronal cell death. Tau protein and Aβ fragment 1–42 have been investigated so far in cerebrospinal fluid as a potential AD biomarkers. However, an urgent need to identify novel biomarkers which will capture disease in the early stages and with better specificity remains. High-throughput proteomic and pathway analysis of hippocampal tissue provides a valuable source of disease-related proteins and biomarker candidates, since it represents one of the earliest affected brain regions in AD.

Results

In this study 2954 proteins were identified (with at least 2 peptides for 1203 proteins) from both control and AD brain tissues. Overall, 204 proteins were exclusively detected in AD and 600 proteins in control samples. Comparing AD and control exclusive proteins with cerebrospinal fluid (CSF) literature-based proteome, 40 out of 204 AD related proteins and 106 out of 600 control related proteins were also present in CSF. As most of these proteins were extracellular/secretory origin, we consider them as a potential source of candidate biomarkers that need to be further studied and verified in CSF samples.

Conclusions

Our semiquantitative proteomic analysis provides one of the largest human hippocampal proteome databases. The lists of AD and control related proteins represent a panel of proteins potentially involved in AD pathogenesis and could also serve as prospective AD diagnostic biomarkers.

【 授权许可】

   
2013 Begcevic et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Huang Y, Mucke L: Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
• [2]Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8:663-672.
• [3]Henry MS, Passmore AP, Todd S, McGuinness B: The development of effective biomarkers for Alzheimer's disease: a review. Int J Geriatr Psychiatry 2013, 28:331-340.
• [4]Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38:643-648.
• [5]Sunderland T, Linker G, Mirza N, Putnam KT: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Jama 2003, 289:2094-2103.
• [6]Holtzman DM: CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 2011, 32(Suppl 1):S4-S9.
• [7]Hampel H, Burger K, Teipel SJ, Bokde AL: Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008, 4:38-48.
• [8]Blennow K, Wallin A, Agren H, Spenger C: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995, 26:231-245.
• [9]Kohnken R, Buerger K, Zinkowski R, Miller C: Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000, 287:187-190.
• [10]Mattsson N, Zetterberg H, Blennow K: Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis 2010, 2010:1-5.
• [11]Albert MS, DeKosky ST, Dickson D, Dubois B: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
• [12]Korolainen MA, Nyman TA, Aittokallio T, Pirttila T: An update on clinical proteomics in Alzheimer's research. J Neurochem 2010, 112:1386-1414.
• [13]Zellner M, Veitinger M, Umlauf E: The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol 2009, 118:181-195.
• [14]Donovan LE, Higginbotham L, Dammer EB, Gearing M: Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. Proteomics Clin Appl 2012, 6:201-211.
• [15]Andreev VP, Petyuk VA, Brewer HM, Karpievitch YV: Label-Free Quantitative LC-MS Proteomics of Alzheimer's Disease and Normally Aged Human Brains. J Proteome Res 2012, 11:3053-3067.
• [16]Sultana R, Boyd-Kimball D, Cai J, Pierce WM: Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 2007, 11:153-164.
• [17]Braak H, Braak E: Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991, 1:213-216.
• [18]Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
• [19]Crecelius A, Gotz A, Arzberger T, Frohlich T: Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-DDIGE. Proteomics 2008, 8:1276-1291.
• [20]Dickson DW: Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 2004, 114(1):23-27.
• [21]Di Rosa G, Odrijin T, Nixon RA, Arancio O: Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci 2002, 19(1–2):135-141.
• [22]Veeranna , Kaji T, Boland B, Odrljin T, Mohan P, Basavarajappa BS, Peterhoff C, Cataldo A, Rudnicki A, Amin N, Li BS, Pant HC, Hungund BL, Arancio O, Nixon RA: Calpain mediates calcium-induced activation of the erk1, 2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol 2004, 165(3):795-805.
• [23]Schutzer SE, Liu T, Natelson BH, Angel TE: Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010, 5:e10980-e10986.
• [24]Prassas I, Chrystoja CC, Makawita S, Diamandis EP: Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Med 2012, 10:39-51. BioMed Central Full Text